Gedea Biotech receives approval to initiate the pivotal NEFERTITI-2 clinical study documenting the performance of pHyph for treatment of bacterial vaginosis
· This pivotal study aims to confirm the safety and efficacy of pHyph in treating and preventing BV recurrence · Patient recruitment will now be initiated and 5 Swedish clinics are planned to attend · Previous studies in BV have demonstrated pHyph to have a BV cure rate in line with antibiotics on the market, with superior safety profile and without causing the secondary candida infections and the high recurrence seen when treating BV with antibiotics Lund, Sweden, November 8, 2023. Swedish women’s health company Gedea Biotech developing antibiotic-free treatments, today announced